The Babraham Institute undertakes world-leading research into understanding the biology of how our bodies work, including what changes as we age and during disease. Our research is split into three programmes: Epigenetics, Signalling, and Immunology, supported by strategic programme grants from the Biotechnology and Biological Sciences Research Council (BBSRC) and additional funding from research councils, the EU and charities.

We maximise the impact of our research through Knowledge Exchange, Commercialisation and Public Engagement activities. We do this by collaborating with other academics, policy makers, charities, schools, the general public and industry, including companies on the Babraham Research Campus. Commercialisation is achieved in collaboration with the Institute’s wholly-owned trading arm, Babraham Institute Enterprise Limited.



New understanding of cell stability with potential to improve immune cell therapies

Findings highlight pathway to remove unstable cells

Researchers identify the origin of potentially dangerous unstable cells


Settling the score on immune cell receptor function

The IL-7 receptor unlocks access to antibody genes.

Researchers confirm antibody diversity requires cell growth receptor.


Welcoming Dr Ian McGough to the Signalling research programme

Introducing Dr McGough and our new group leader intake

Appointments span the Signalling and Epigenetics research programmes


Professor Wolf Reik steps down as Institute Director

Board of Trustees announcement

Dr Simon Cook is appointed Interim Director

Access our Science Facilities

Biological Support Unit
Biological Chemistry
Flow Cytometry
Mass Spectrometry
Gene Targeting

Providing comprehensive tools and analysis for life sciences Key services Bioinformatics Analysis Consultancy Statistics Training Software Infrastructu


The Imaging Facility provides a high quality microscopy and image analysis service for Babraham Institute scientists and the broader research community. We offer tra


Next Generation Sequencing technology has revolutionised post-genomics studies of gene expression, genetic regulation and nuclear dynamics. The Sequencing Facility provid

Biological Support Unit

Our state-of-the-art Biological Support Unit provides housing and care for pathogen-free rodents. It supports research across the Institute as well as providing services


The Lipidomics Facility undertakes the detection and identification of lipids, with a focus on providing biological meaning to these generated lipid profiles through bios

Biological Chemistry

To provide a research interface between chemistry and biology to solve biological questions. Key services Chemical synthesis (bio-active molecules, fluorescent or i

Flow Cytometry

The Babraham Institute Flow Cytometry Core Facility offers high quality service and state-of-the-art instrumentation to members of Babraham Institute and external users.

Mass Spectrometry

The primary role of the Facility is to apply state of the art techniques in mass spectrometry to address important biological questions, within the remit of the Institute

Gene Targeting

To deliver gene targeting capabilities including the production of transgenic mouse models. Key services Generation of mouse models; ranging from single nucleoti


L-selectin/CD62L: not just a lymph node homing receptor on T-cells

Prof. Ann Ager

Professor of Cellular Immunity and Immunotherapy, University of Cardiff

No Upcoming Events Currently

Key visitor pages

Members of the public may wish to look at the following pages to find out how the Babraham Institute works with and for society:

The following pages may be of particular interest to those in the Academic community:

Members of the media and journalists may wish to visit the following sections for further details about our work:

Inhibitory feedback control of NF-κB signalling in health and disease.

Prescott JA, Mitchell JP, Cook SJ,

The Biochemical journal
478 13: 16 Jul 2021

PMID: 34269817

IL-7R signaling activates widespread V and D gene usage to drive antibody diversity in bone marrow B cells.

Baizan-Edge A, Stubbs BA, Stubbington MJT,

Cell reports
36 2: 13 Jul 2021

PMID: 34260907